Drugs / IIV4
IIV4
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 48 trials · 1 met primary | ||||||
| Phase 4 | NCT06503900 | Sep 2024 → Aug 2025 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT05480436 | Aug 2022 → Jan 2023 | COVID-19, hemolytic anemia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT05298800 | Oct 2021 → Dec 2022 | — | Centers for Disease Control and Prevention, China | Unknown | No outcome recorded |
| Phase 4 | NCT05028361 | Oct 2021 → Mar 2023 | — | Duke University | Completed | Met primary |
| Phase 4 | NCT05144464 | Sep → Nov 2021 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
| Phase 4 | NCT05079152 | May 2021 | influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT04790851 | Mar → Sep 2021 | COVID-19, influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT04559204 | Sep → Nov 2020 | influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT03600428 Comparator | Oct 2018 → Mar 2020 | childhood onset asthma, influenza, vaccinia | Vanderbilt University Medical Center | Completed | Met primary |
| Phase 4 | NCT02967393 Comparator | Oct 2016 → Feb 2017 | asthma | Vanderbilt University Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IIV4 | “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 20249“This study assessed the immunogenicity and safety of a quadrivalent influenza split-virion vaccine (IIV4) in children with and without prior influenza vaccination.” PMID 39993940 ↗ Feb 2025 “quadrivalent inactivated influenza vaccine (IIV4)” PMID 35342923 ↗ Apr 2022 |
| Known as | quadrivalent inactivated influenza vaccine | “quadrivalent inactivated influenza vaccine (IIV4)” NCT04559204 ↗2“IIV4 (quadrivalent inactivated influenza vaccine)” NCT06503900 ↗ “quadrivalent inactivated influenza vaccine (IIV4)” NCT05028361 ↗ |
| Known as | quadrivalent influenza split-virion vaccine | “This study assessed the immunogenicity and safety of a quadrivalent influenza split-virion vaccine (IIV4) in children with and without prior influenza vaccination.” PMID 39993940 ↗ Feb 2025 |
| Known as | quadrivalent split-virion inactivated influenza vaccine | “an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine” PMID 35931636 ↗ Jul 2022 |
| Modality | Vaccine | “quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®)” NCT02967393 ↗ |
| Route | Intramuscular | “0.5 mL intramuscular injection” NCT02967393 ↗ |